A ngiotensin II (Ang II), the final effector in the / \ renin-angiotensin system (RAS), is generated J. X . through a cascade of proteolytic reactions including cleavage of angiotensinogen by renin to release the decapeptide angiotensin I, which is further converted into Ang II by the angiotensin converting enzyme (ACE).
A ngiotensin II (Ang II), the final effector in the / \ renin-angiotensin system (RAS), is generated J. X . through a cascade of proteolytic reactions including cleavage of angiotensinogen by renin to release the decapeptide angiotensin I, which is further converted into Ang II by the angiotensin converting enzyme (ACE). 1 In general terms, two theoretical approaches can be considered to interfere with the RAS function in the treatment of hypertension. It is first possible to decrease the production and/or extracellular concentration of Ang II. In spite of efforts to develop agents acting at the level of renin, 2 ACE inhibitors 3 constitute at present the most successful antihypertensive drugs interfering with the RAS. However, they also inhibit other actions of ACE on kinins, enkephalins, or substance P and do not decrease the production of Ang II generated locally via other enzymatic systems. 4 The second approach, which may thus be valuable, acts downstream in the RAS and is based on the inhibition of the Ang II-receptor interaction. Ang II analogues substituted at the carboxy terminus phenylalanine were first used. 5 " 8 They combine with the receptor in the place of Ang II but do not trigger the transduction machinery because phenylalanine in position 8, which is crucial for Ang II biological activity, has been substituted. More recently, potent nonpeptide analogues specific for type I 9 and type 2 10 receptors have also been designed. Alternatively, one can conceive anti-Ang II molecules that bind to Ang II but not to its receptor.
The present studies were performed with such an agent prepared by using the approach pioneered by Biro" and expanded by Blalock and coworkers, 12 -13 who from the complementarity of codons for hydrophobic and hydrophilic amino acids, predicted the interaction of peptides or proteins encoded by complementary strands of DNA read in the 5' to 3' direction. Blalock and coworkers (Bost et al 14 ) further suggested that DNA complementarity might explain the binding of peptidic ligands to their receptors. Indeed, specific binding has been demonstrated between hormones such as adrenocorticotropic hormone, 15 luteinizing hormone-releasing hormone, 16 •y-endorphin, 17 and insulin 18 and their respective complementary peptides referred to as antipeptides; moreover, pofyclonal antibodies raised against these antipeptides have been shown to react with membrane receptors for the corresponding ligands including adrenocorticotropic hormone, 15 opiate peptides, 17 gonadotropin-releasing hormone, 19 insulin, 18 fibronectin, 20 and vasopressin. 21 Nevertheless, the hypothesis put forward by Blalock is at present much debated on theoretical grounds. 22 Indeed, the theory does not seem to apply to all hormone peptides since, for instance, parathyroid hormone does not react with its complementary peptide. 23 In addition, the prediction that inverse complements of peptide ligand transcripts are homologous with the transcripts of their receptors has not been borne out by the recent cloning of the substance P receptor. 24 Finally, the foreseeable inhibition of hormone ligand physiological effects by the antipeptide has been exceptionally reported in vivo as well as in vitro. 16 In the case of Ang II, Elton et al 25 have shown that a rat Ang II antipeptide inhibits binding of Ang II to its receptors and can induce anti-Ang II receptor antibodies. These results are, however, still controversial 26 -27 and, in addition, other Ang II antipeptides seem to react directly with Ang II receptors. 28 -29 In the present study, we showed that the antipeptide encoded by the RNA complementary to human Ang II messenger RNA (mRNA) (hllA) 30 markedly inhibits the binding of 125 I-Ang II to hepatic or immunoglobulin receptors but does not itself bind to these receptors. In addition, we have used the specificity of seven monoclonal antibodies (mAbs) identifying four distinct epitopes on the Ang II molecule 31 to probe the interaction of hllA and Ang II: inhibition of binding of Ang II to the mAbs is 100 times more efficient with the one antibody specific for the area of the Ang II molecule reported as implicated in receptor recognition. This may suggest that hllA mimics, at least in part, the binding region of the receptor. Finally, we demonstrate for the first time that an antiligand molecule can antagonize physiological properties of the ligand not only in vitro but also in vivo: indeed, on mesangial cells, hllA abolishes the Ang II-induced cytosolic free calcium concentration ([Ca 2+ ]i) increase and prostaglandin E? (PGE^) release and, in the rat, markedly reduces the hypertensive response to Ang II.
Methods

Preparation and Labeling of the Antipeptide hllA
The amino acid sequence of hllA was derived from the RNA sequence complementary to the segment of the human angiotensinogen mRNA that encodes Ang II. 30 This complementary sequence was read in the 5' to 3' direction and in the same reading frame. The hllA was then synthesized by standard solid phase methods and purified (more than 95%) by reverse-phase highperformance liquid chromatography (HPLC) (Appligene, Strasbourg, France). The hllA (20 fig) was labeled with iodine-125 (2 mCi) using chloramine T as previously described with slight modifications. 30 Monoiodinated hllA (2,000 Ci/mmol) was obtained after purification by HPLC on a nucleosil 5 ^m C18 column using an isocratic elution with a solvent mixture acetonitrile (16%)-triethylamine phosphate buffer 0.15 M (84%), pH 2.55. To obtain tritium-labeled hllA, the peptide was first diiodinated with an excess of sodium iodide and chloramine T. then purified by HPLC and dehalogenated in the presence of tritium gas and palladium dioxide as catalyst as previously described. 32 The tritiated peptide was then purified on a TSK (ODS-120T, 5 fim) 4.6x250 mm column. Its specific activity, calculated from absorbance and radioactivity counting, was 14 Ci/mmol.
Human Ang II (Sigma Chemical Co., St. Louis, Mo.) was labeled exactly as hllA to specific activities of 2,000 Ci/mmol and 57 Ci/mmol, respectively, for the iodinated and tritiated forms.
Binding to Anti-Angiotensin II Monoclonal Antibodies
We used in this study seven mAbs previously produced and characterized in our laboratory 31 and reactive with at least four distinct epitopes on Ang II molecule ( Figure 1 ). The mAbs from group 1 are specific for an Ang II epitope requiring phenylalanine at position 8 (Phe 8 ) with a free COOH-terminus. They are subclassified into groups IA and IB, respectively, according to their reactivity with iodine-125-labeled Ang II. The mAbs from group IB identify an iodinationsensitive epitope that encompasses Phe 8 and tyrosine at position 4 (Tyr 4 ). The mAbs from group 2 are also specific for Phe 8 but, in addition, recognize this amino acid when its COOH group is implicated in a peptidic linkage as in angiotensin I. The mAbs from group 3 remain reactive with Phe 8 and Asp'-substituted Ang II analogues, a finding that suggests that they define a "central" epitope on Ang II.
Binding of iodine-125-or tritium-labeled Ang II or hllA by the anti-Ang II mAbs or a control mAb (CDV 135) specific for neutral endopeptidase 33 was tested by liquid-phase radioimmunoassay (RIA) as previously described. 31 Briefly, the radiolabeled ligand in 20 jtl phosphate-buffered saline containing 0.1% bovine serum albumin (PBS-BSA) was reacted for 1 hour at room temperature with 20 fi\ of 1:10 diluted hybridoma supernatant in the absence or the presence of hllA or Ang II. Bound radioactivity was precipitated using 20 /il sheep anti-mouse immunoglobulin followed by poh/eth-ylene glycol (PEG 6000, Merck, Darmstadt, FRG) at a final concentration of 10% (wt/vol). The precipitates were washed in 10% PEG and those containing iodine-125 ligand were counted without further processing, whereas those containing tritiated ligand were dissolved in IN NaOH, transferred into scintillation vials, and counted after addition of scintillation fluid.
Binding to Angiotensin II Hepatic and Mesangial Receptors
Rat hepatocyte membranes were prepared according to a modified Neville 34 procedure and incubated with iodine-125-labeled Ang II or hllA in 200 ml of 50 mM Tris, pH 7.4, containing 10 mM MgClj, 100 mM NaCl, 10" 4 M phenylmethylsulfonyl fluoride, and 0.1% BSA. The reaction was carried out for 1 hour at room temperature in the Millititer GV96 well filtration plate (Millipore, Bedford, Mass.) in the absence or the presence of unlabeled Ang II or hllA. Separation of bound from free ligand was achieved by vacuum filtration of the well content followed by four washings in the buffer. Filter discs were subsequently cut from the bottom of the plate and counted. To test the binding of the tritium-labeled ligands, the incubation step was performed in polystyrene round bottom multiwell plates (Nunc, Denmark), and the content of each well was subsequently vacuum filtered through 0.45 -fim cellulose nitrate filters (Whatman, England) to separate bound from free ligand. Filters were then washed four times in the buffer, transferred into scintillation vials, dissolved in 1 ml dioxan (Fluka, Buchs, Switzerland), and counted after addition of scintillation fluid.
Rat mesangial cells were cultured from isolated glomeruli in 10% fetal calf serum according to the methods previously described. 35 Mesangial cells appeared after 7-14 days in culture and reached confluency by day 21. Cells obtained after one passage were cultured in 12-well culture plates, rinsed twice, and incubated under constant shaking in a 37°C waterbath in 400 jtl of buffer A (10 mM HEPES, pH 7.4, containing 135 mM NaCl, 5 mM KC1, 1 mM Na 2 HPO 4 , 1.8 mM CaCl 2 , 0.5 mM MgSO 4 , and 10 mM glucose) supplemented with 0.1% BSA in the presence of iodine-125-labeled Ang II or hllA. After 5 or 15 minutes incubation, the medium was removed by aspiration; the cells were washed three times with 0.16 M NaCl and dissolved in 400 /xl NaOH 1 M for 1 hour at 4°C, and associated radioactivity was measured. Protein content was determined according to Bradford, 36 and results were normalized to 20 fig protein. Nonspecific binding was defined as bound radioactivity in the presence of 1 p.M unlabeled ligand.
Effects of fill A on Biological Properties of Cultured Mesangial Cells
Prostaglandin production was measured on subcultured rat mesangial cells. Cells were grown to confluency in six-well culture dishes, cultured for 24 hours in serum-free RPMI 1640 without glutamine medium, rinsed twice, and incubated for 5 minutes at 37°C in 1 ml of buffer A. The cells were then exposed to Ang II (1 nM-1 fiM) or bradykinin (100 nM) for 5 minutes at 37°C in 1 ml of the same buffer. To test the antagonistic effects of hllA (100 nM-10 ^M), the peptide was added to the incubation medium 1 minute before and during the 5-minute incubation period with Ang II or bradykinin. At the end of the incubation period, the media were collected and stored at -20°C before use. PGE2 was measured by RIA according to Dray et al. 37 Results are expressed as nanograms per milligram protein determined according to Bradford, 36 and given as mean±SEM. Statistical significance of the effect of hllA on the PGE2 release induced by Ang II or bradykinin was tested by one-factor analysis of variance.
The [Ca 2+ ]i was measured in subcultures (4 to 6 passages) of human mesangial cells 38 grown to confluency on coverslips according to the method described by Mene et al. 39 After rinsing in buffer A supplemented with 0.1% BSA, cells were loaded at 3TC for 60 minutes with fura-2 acetoxymethylester (4 /xM) added to this buffer. The loaded cells were washed twice and then placed at a 60° angle in a quartz cuvette containing 2 ml buffer A supplemented with 0.25 mg/ml BSA. The experiments were carried out at 37°C under constant stirring. Fluorescence was monitored continuously in a Perkin-Elmer model LS-5 spectrofluorimeter before and after addition of the tested agents (Ang II, 100 nM; hllA, 10 ^.M) or vehicle, using 339 nm excitation/500 nm emission wavelengths with 5-and 20-mm slit width, respectively. Calibration of the Ca 2+ -dependent fluorescence for each monolayer was obtained by addition of 20 /iM ionomycin (maximal fluorescence, F^) followed by 4 mM EGTA in 60 mM tris-HCl, pH 10.5 (minimal fluorescence, F m ) . The antagonistic effect of hllA was tested as in the PGE2 production studies. [Ca 2+ ], was calculated using the previously described formula: 
Effects of hllA on Rat Hypertensive Response to Angiotensin II
Sprague-Dawley male rats (350-400 g body wt) were anesthetized and placed under assisted respiration (tidal volume 3 ml, 80 respirations per minute) using a Harvard pump (Harvard Apparatus, South Natick, Mass.). A catheter was inserted in the carotid artery and connected to a Statham P23Db captor unit (Statham Division, Gould Inc., Oxnard, Calif.) to monitor blood pressure. Another catheter in the penile vein served for all intravenous injections. Rats were given d-tubocurarin chloride (Sigma) (1 mg/kg i.v.), hexamethonium bromide (Fluka) (10 mg/kg i.v.), prazosin (Sigma) (1 mg/kg i.v.), and their vagal nerves were cut. Under these conditions, the mean blood pressure was 83 ±8 mm Hg (n = 12), and a 100 ng/kg Ang II bolus induced a reproducible hypertensive response. To evaluate the effects of the complementary peptide, the latter was administered either as an intravenous bolus (0.1, 0.3, 1, or 2 mg/kg) 5 minutes before Ang II injection or as a continuous intravenous infusion (50-200 jig/kg/min for 20 minutes); the Ang II bolus was then given 15 minutes after the beginning of the infusion. The dose-dependent antihypertensive effect of hllA was analyzed by three-factor analysis of variance and regression analysis. Additional experiments were /kg i.v.), and the a 2 -agonist M7 (synthesized by G. Regnier, IDRS) (10 jig/kg i.v.). Finally, the competitive or noncompetitive type of the inhibitory effects of hllA was tested after a slightly modified protocol. Rats were anesthetized, placed under assisted ventilation as above, but their brains and spinal cords were destroyed. 41 While maintained at 36°C, they were given repetitive Ang II bolus at increasing doses (0.03-2 tig/kg) at 5-minute intervals to construct the Ang II dose-response curve. The hllA was subsequently administered as a continuous intravenous infusion (200 tig/kg/min), and the Ang II dose-response curve was then repeated following the above schedule except that Ang II doses ranged from 0.25 to 32 tig/kgEach set of experiments was performed on a group of four animals.
Results
Sequence of the Antipeptide hllA
The synthesis of the Ang II complementary peptide was based on the sequence of human angiotensinogen mRNA reported by Kageyama et al. 30 Figure 2 shows the amino acid and mRNA sequences for human Ang II together with the derived nucleotide sequence of the complementary RNA and the corresponding amino acid sequence of the antipeptide hllA. The hydropathic profiles of Ang II and hllA are presented in Figure 3 .
Lack of Binding of hllA to Anti-Angiotensin II Monoclonal Antibodies and Angiotensin II Hepatic and Mesangial Receptors
Since hllA shares four amino acids with Ang II, we first determined whether the two peptides were antigenically related. For this purpose, we studied binding of the peptides to seven mAbs specific for four distinct epitopes on Ang II. 31 As shown in Figure 4 , the amount of 125 I-Ang II bound by the mAbs was between 1.21 and 3.10 fmol (27-69% of the input) and was reduced by more than 90% in the presence of an excess of unlabeled Ang II. As expected, the only exception was mAb 11 (group IB), which recognizes an iodination-denatured epitope on Ang II. Binding by this antibody as well as by the control mAb CDV 135 was very low (0.37 and 0.17 fmol, respectively) and only partially inhibited by cold Ang II (62% and 30%, respectively). By contrast, under the same experimental conditions, the quantity of hllA fixed to the mAbs did not exceed 0.13 fmol and was not influenced by an excess of Ang II. Since this low level of binding could be related to low affinity binding of the antipeptide by some mAbs, experiments were repeated with a 35-fold increase in the '"I-hllA offered ( Table 1 ). The amount of 125 I-hIIA bound by the anti-Ang II mAbs was then between 0.75 and 1.41 fmol (less than 1% of the input) and remained lower than that bound by the control mAb CDV 135. In addition, it was not decreased by an excess of either unlabeled hllA or Ang II, thus suggesting nonspecific binding of the ligand to the mAbs. Comparable data were obtained with the tritiated antipeptide (not shown). These results showed that mAbs directed to different epitopes on the Ang II molecule did not recognize those expressed on the complementary peptide and suggested that the two peptides probably assumed very different three-dimensional spatial conformations.
This was confirmed by studies in which increasing amounts of 125 I-hIIA were reacted with rat hepatocyte membranes in the absence or the presence (10 nM) of unlabeled Ang II or hllA. As shown in Table 2 , binding of Ang II to hepatic membranes was easily demonstra- (Table 2) , not saturable, and poorly inhibited (0-12%) by 10 nM of either unlabeled Ang II or hllA in a range of input from 14 to 344 fmol. To ensure that the lack of binding of hllA to Ang II hepatic receptor was not due to iodination-induced alterations of the complementary peptide, the same experiments were carried out with tritium-labeled ligands ( Table 2 ). The amounts of offered Ang II and hllA took into account the low specific activity of the tritiated ligands (which required higher inputs than those used for iodine-125-labeled peptides) and were selected to obtain equivalent quantities of bound peptide. When approximately 500 fmol hllA and Ang II were incubated with hepatic membranes, only 2 fmol hllA was fixed as compared with 31 fmol Ang II. In the presence of 10 nM cold Ang II or hllA, binding of the antipeptide was inhibited only by 6% and 11%, respectively, whereas Ang II fixation was decreased by 93%. When increasing amounts of hllA were offered, hllA binding augmented roughly proportionally but remained noninhibitable by an excess of Ang II or hllA. Very similar results were obtained when 43.6 fmol hllA were incubated with mesangial cells: only 0.047 and 0.069 fmol were membrane associated after 5 and 15 minutes of incubation. Binding was not or poorly (less than 10%) modified by an excess of hllA. Under similar conditions, cells incubated with 24.8 fmol l23 I-Ang II bound 0.54 and 1.35 fmol Ang II at 5 and 15 minutes, respectively. Binding was inhibited by more than 90% by an excess of unlabeled Ang II. These results thus indicated that in two distinct membrane receptor systems exhibiting high specific binding capacity for Ang II, binding of the antipeptide was very low and nonspecific as was its fixation on anti-Ang II mAbs.
Inhibition of Angiotensin II Binding to Hepatic Receptors by hllA
Experiments were carried out at a fixed concentration of Ang II (2.4x10"" M) that gave 10% of the plateau binding value. Both hllA and Ang II induced a dosedependent inhibition of Ang II binding ( Figure 5A ). The inhibition was complete for peptide concentrations of approximately 10 fiM (hllA) and 10 nM (Ang II), and specific since in the same range of concentrations the control peptide bradykinin reduced by less than 25% the binding of Ang II to its receptor. However, hllA was a less potent inhibitor than Ang II, as indi- (0) 2630 (0) 7.01 (6) 1.77 (11) cated by IC» values that were 2 x 10~7 M and 7 x 10~1 0 M, respectively. Very similar results were obtained when parallel experiments were performed with mesangial cells instead of hepatic membranes.
Inhibition of Angiotensin II Binding to Monoclonal Anti-Angiotensin II Antibodies
The binding of 125 I-Ang II to all anti-Ang II mAbs defining different epitopes was inhibited in a dosedependent manner in the presence of increasing concentrations of hllA. However, as shown in Figure 5B , hllA was a rather poor inhibitor of Ang II binding to mAbs from group 1 and 2 but markedly reduced the binding to mAb 133, which is specific for the Ang II sequence probably involved in receptor binding. The IQo (5 x 10" 7 M) for the latter antibody was close to that measured in the binding inhibition experiments carried out with hepatocyte membranes (2xlO~7 M).
hllA Antagonizes the Physiological Effects of Angiotensin II on Cultured Mesangial Cells
We then tested the effects of hllA on PGE2 synthesis induced by Ang II in rat subcultured mesangial cells. As shown in Figure 6 (left panel), Ang II (1 nM-1 fiM) elicited a dose-dependent increase in PGEj production that reached a plateau from 100 nM Ang II. The antipeptide hllA (100 nM-10 ixM) did not affect the basal PGE^ production but inhibited in a dose-dependent manner the effects of 100 nM Ang II (p<0.05) ( Figure 6 , right panel). Complete inhibition was achieved at 10 fiM hllA. This inhibition was specific since hllA did not modify the bradykinin-induced PGEr elease by the same mesangial cell cultures (basal, 0.48+0.04 ng PGEz/mg protein; 100 nM bradykinin, 1.08+0.17; 100 nM bradykinin plus 10 fiM hllA, 1.10+0.25, NS versus bradykinin, n=l).
Parallel inhibitory effects were observed on the [Ca 2+ ]| transient increase in response to Ang II stimulation (Figure 7) in human subcultured mesangial cells. The [Ca 2+ ]j resting level in these cells was 110+6 nM (n=12). Incubation with 100 nM Ang II induced an increase in [Ca 2+ ]j that peaked within 15 seconds at 169±12 nM (p<0.001 versus basal value, n=7) and then returned to the baseline in 60-90 seconds. The antipeptide alone did not modify significantly the basal value (10 fiM hllA, 113±9 nM, n=5) but antagonized the effects of Ang II on [Ca 2+ ]; (100 nM Ang II plus 10 /AM hllA, 120+12 nM, n=5,p<0.05 versus 100 nM Ang II alone).
MIA Reduces the Rat Hypertensive Response to Angiotensin II
We first established the dose-response curve of the Ang II pressor effects by injecting intravenously increasing quantities of Ang II in rats anesthetized and premedicated with hexamethonium and prazosin. To test the antagonistic effects of the antipeptide, we selected a dose of 100 ng/kg Ang II, which induced a 50-65 mm Hg increase in blood pressure corresponding to the half-maximal response. When Ang II was given 5 minutes after a single intravenous injection of 0.1-2 mg/kg hllA, the latter failed to blunt Ang II-induced hypertension. However, when administered as a continuous intravenous infusion (50-200 /ig/kg/min), the antipeptide reduced dose-dependently (p<0.01) the hypertensive response to Ang II (Table 3) . When the rats were pretreated with perindoprilate, an inhibitor of ACE, the antipressive effect of hllA at a dose of 50 /ig/kg/min (Table 3 ) was significantly increased (p<0.01). This inhibition was specific since hllA infused at a rate of 200 Mg/kg/min did not alter the effects of other pressor agents, including the HT 2 -agonist serotonin (100 Mg/kg i.v.), the apagonist phenylephrine (4 /ig/kg i.v.), and the oi-agonist M7 (10 ^g/kg i.v.).
In addition, to identify the type of hlLA-induced inhibition of Ang II effects, we compared the doseresponse curves depicting the increase in blood pressure after Ang II injection in four rats before and during an infusion of 200 /xg/kg/min hllA. As shown in Figure  8 , the antipeptide caused a dramatic shift to the right of the dose-response curve: under hllA infusion, 32 /ig/kg Ang II were required to obtain the maximal pressor response as compared with 2 /ig/kg in noninfused rats. The parallelism of the two curves suggested that hllA and the Ang II vascular receptors were competitive inhibitors at the same binding site on Ang II.
Discussion
The present study investigates the effect on the interaction of Ang II with its receptors of an anti-Ang II molecule, hllA, encoded by an RNA complementary to human Ang II mRNA. We first established that the antipeptide hllA could inhibit the binding of Ang II to both membrane and immunoglobulin receptors without reacting with these receptors. Indeed, although hllA shares four amino acids with human Ang II, it failed to bind either to hepatic membranes or mesangial cells or to any anti-Ang II mAb. The negative results of the binding experiments are probably not attributable to low affinity interaction since incubation with hllA concentrations up to 80-fold greater than those of Ang II did not unmask any specific fixation, i.e., fixation inhibited by an excess of Ang II or hllA. Despite the absence of binding to Ang II receptors, hllA is a potent inhibitor of Ang II-receptor interaction. Its IQo (2xlO~7 M) in a system using Ang II receptor-rich hepatic membranes is very close to that reported for the rat antipeptide with rat adrenal particles as a source of Ang II receptors. 25 Also hllA shares four amino acids with TBI-22, 28 an octapeptide that inhibits the binding of Ang II to rabbit liver solubilized receptors, but this inhibition appears to result from competition between the two ligands for Ang II receptors. These results thus show that a conserved backbone of four amino acids is not sufficient to determine a spatial conformation identified by the receptor. They also do not support the assumption 28 that tyrosine in position 4 is critical per se for receptor recognition since this amino acid is conserved in hllA.
In spite of the relatively high IQo measured on hepatic membranes, the interaction between hllA and Ang II has probably a relatively high affinity since hllA was able to antagonize the physiological responses to Ang II not only in vitro but also in vivo. Although the hypothesis put forward by Blalock and coworkers 12 -13 has been confirmed in a number of systems by the ability of the antipeptide to inhibit ligand binding to the receptor 15 II. It can also induce a specific dose-dependent inhibition of the Ang II-stimulated PGE? release by mesangial cells. The latter studies were performed on rat mesangial cells because prostaglandin production by human mesangial cells is very low. 38 In vivo intravenous infusion of hllA dramatically reduces the hypertensive response to Ang II. The lack of effect of a single intravenous injection of hllA as well as the requirement of relatively high rates of hllA infusion are probably due in part to rapid degradation of the peptide in the circulation. Indeed, pretreatment of rats with the ACE inhibitor perindoprilate (100 /ig/kg) increased the antagonistic effects of hllA, which implies that ACE might be involved at least in part in the degradation of hllA in the blood.
To design more efficient, possibly nonpeptide, analogues of hllA, it is crucial to delineate further the spatial conformation of the hllA-Ang II combining site. With this objective in mind, we performed binding inhibition experiments in which the binding of Ang II to the various monoclonal paratopes was studied in the presence of increasing doses of hllA. As expected for an antigen-antibody reaction implicating a small peptide, Ang II binding was inhibited dose-dependentry by hllA for all mAbs tested. However, the degree of inhibition measured by hllA IQo values was greatly influenced by ; group 2 mAbs=0.9-1.2x10' M" 1 ). 31 These results suggest that the epitope defined by mAb 133 is tightly related to, if not identical with, the hlLA-Ang II combining site.
This epitope is also likely to be involved in receptor recognition. First, it is identified by mAb 133 on Ang II peptide analogues substituted at the carboxy or amino terminus, 31 which are known to bind the Ang II receptor but do not trigger the transduction machinery. Second, mAb 133 is a 100-fold more potent inhibitor of Ang II binding to hepatic membrane receptors (ICJO=1O~" M) than mAbs pertaining to groups 1 and 2 (ICJO=1O~' M) (personal data). This suggests that the sites of the Ang II molecule implicated in receptor recognition and hlLA binding are very close, if not identical, and favors conformational homology between hlLA and the Ang II combining region on the receptor or the monoclonal antibody mAb 133. Recent cloning and expression of a complementary DNA encoding Ang II type-1 receptor 44 - 45 does not solve this issue because the longest peptide sequence (Val-His-Pro) common with hlLA seems to be located in the cytoplasm between transmembrane domains HI and IV. We have grown diffraction quality crystals with the Fab fragment of a highly purified isoform of mAb 133 either alone or combined with Ang II, 46 and the sequence of variable regions of this antibody has been recently worked out (Garcia KC et al, unpublished results) . Further studies will compare data obtained from x-ray diffraction analysis of these crystals and especially amino acid residues that make critical contacts with Ang II in the mAb 133-Ang II complex, with the antipeptide sequence.
Despite the drawbacks inherent in the therapeutic use of peptides (intravenous administration, short halflife), this article presents one of the very first pharmacological applications of compounds derived from the strategy defined by Blalock. Further studies on the interaction of Ang II and hlLA may lead to a new class of antihypertensive drugs that act at the terminal stage of the RAS cascade without binding to the receptor.
